



Altimune to Participate in Two Upcoming Investor Conferences

November 5, 2025 at 7:30 AM EST

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for one-on-one meetings at the following investor conferences:

- **Stifel 2025 Healthcare Conference**
Wednesday, November 12, 2025
Fireside Chat at 10:00 a.m. ET
- **Jefferies Global Healthcare Conference**
Thursday, November 20, 2025
Fireside Chat at 8:00 a.m. GMT

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [X](#)

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:

Elliot Fox
Real Chemistry
efox@realchemistry.com

This press release was published by a CLEAR® Verified individual.



Source: Altimune, Inc